Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers

被引:10
|
作者
Wright, Margaret E. [1 ,2 ]
Albanes, Demetrius [3 ]
Moser, Ann B. [4 ]
Weinstein, Stephanie J. [3 ]
Snyder, Kirk [5 ]
Mannisto, Satu [6 ]
Gann, Peter H. [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA
[2] Amer Acad Pediat, Elk Grove Village, IL 60007 USA
[3] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA
[4] Kennedy Krieger Inst, Baltimore, MD USA
[5] Informat Management Serv Inc, Silver Spring, MD USA
[6] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland
来源
CANCER MEDICINE | 2014年 / 3卷 / 06期
关键词
Biomarker; diet; phytanic acid; pristanic acid; prostate cancer; METHYLACYL-COA RACEMASE; PROSPECTIVE COHORT; BETA-CAROTENE; FATTY-ACID; DISEASE; PLASMA; METAANALYSIS; CONSUMPTION; METABOLISM; BIOMARKERS;
D O I
10.1002/cam4.319
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phytanic acid is a saturated branched-chain fatty acid found predominantly in red meat and dairy products, and may contribute to the elevated risks of prostate cancer associated with higher consumption of these foods. Pristanic acid is formed during peroxisomal oxidation of phytanic acid, and is the direct substrate of a-Methyl-CoA-Racemase (AMACR)-an enzyme that is consistently overexpressed in prostate tumors relative to benign tissue. We measured phytanic and pristanic acids as percentages of total fatty acids by gas chromatography-mass spectrometry in prediagnostic blood samples from 300 prostate cancer cases and 300 matched controls, all of whom were participants in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study supplementation trial and follow-up cohort. In addition to providing a fasting blood sample at baseline, all men completed extensive diet, lifestyle, and medical history questionnaires. Among controls, the strongest dietary correlates of serum phytanic and pristanic acids were saturated fat, dairy fat, and butter (r = 0.50 and 0.40, 0.46 and 0.38, and 0.40 and 0.37, respectively; all P-values <0.001). There was no association between serum phytanic acid and risk of total or aggressive prostate cancer in multivariate logistic regression models (for increasing quartiles, odds ratios (OR) and 95% confidence intervals (CI) for aggressive cancer were 1.0 (referent), 1.62 (0.97-2.68), 1.12 (0.66-1.90), and 1.14 (0.67-1.94), P-trend = 0.87). Pristanic acid was strongly correlated with phytanic acid levels (r = 0.73, P < 0.0001), and was similarly unrelated to prostate cancer risk. Significant interactions between phytanic and pristanic acids and baseline circulating beta-carotene concentrations were noted in relation to total and aggressive disease among participants who did not receive beta-carotene supplements as part of the original ATBC intervention trial. In summary, we observed no overall association between serum phytanic and pristanic acid levels and prostate cancer risk. Findings indicating that the direction and magnitude of these associations depended upon serum levels of the antioxidant beta-carotene among men not taking beta-carotene supplements should be interpreted cautiously, as they are likely due to chance.
引用
收藏
页码:1562 / 1569
页数:8
相关论文
共 50 条
  • [21] Serum selenium levels and prostate cancer risk A MOOSE-compliant meta-analysis
    Cui, Zhigang
    Liu, Dezhong
    Liu, Chun
    Liu, Gang
    MEDICINE, 2017, 96 (05)
  • [22] Dietary acrylamide intake and the risk of cancer among Finnish male smokers
    Hirvonen, T.
    Kontto, J.
    Jestoi, M.
    Valsta, L.
    Peltonen, K.
    Pietinen, P.
    Virtanen, S. M.
    Sinkko, H.
    Kronberg-Kippila, C.
    Albanes, D.
    Virtamo, J.
    CANCER CAUSES & CONTROL, 2010, 21 (12) : 2223 - 2229
  • [23] Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study
    Song Yao
    Cathee Till
    Alan R. Kristal
    Phyllis J. Goodman
    Ann W. Hsing
    Catherine M. Tangen
    Elizabeth A. Platz
    Frank Z. Stanczyk
    Juergen K. V. Reichardt
    Li Tang
    Marian L. Neuhouser
    Regina M. Santella
    William D. Figg
    Douglas K. Price
    Howard L. Parnes
    Scott M. Lippman
    Ian M. Thompson
    Christine B. Ambrosone
    Ashraful Hoque
    Cancer Causes & Control, 2011, 22 : 1121 - 1131
  • [24] Serum testosterone levels, testis volume, and the risk of prostate cancer: are these factors related?
    Haliloglu, Ahmet Hakan
    Gokce, Ilker
    Ozcan, Cihat
    Baltaci, Sumer
    Yaman, Onder
    TURKISH JOURNAL OF UROLOGY, 2013, 39 (01): : 12 - 15
  • [25] Folate intake, serum folate levels, and prostate cancer risk: a meta-analysis of prospective studies
    Rong Wang
    Yan Zheng
    Jing-Yang Huang
    Ai-Qin Zhang
    Yu-Hao Zhou
    Jie-Ning Wang
    BMC Public Health, 14
  • [26] Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
    Salminen, Jukka K.
    Kuoppamaki, Viivu
    Talala, Kirsi
    Taari, Kimmo
    Makinen, Jussi
    Peltola, Jukka
    Tammela, Teuvo L. J.
    Auvinen, Anssi
    Murtola, Teemu J.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (02) : 307 - 315
  • [27] Role of Serum Creatinine Levels in Prognostic Risk Stratification of Prostate Cancer Patients
    Gu, Xingbo
    Wu, Jiaojiao
    Liu, Xuefeidan
    Hong, Yun
    Wu, Yaoxi
    Tian, Ye
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [28] Serum uric acid levels and risk of developing preeclampsia
    Corominas, Ana I.
    Balconi, Silvia M.
    Palermo, Mario
    Maskin, Bernardo
    Damiano, Alicia E.
    MEDICINA-BUENOS AIRES, 2014, 74 (06) : 462 - 471
  • [29] Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG
    Graff, Rebecca E.
    Judson, Gregory
    Ahearn, Thomas U.
    Fiorentino, Michelangelo
    Loda, Massimo
    Giovannucci, Edward L.
    Mucci, Lorelei A.
    Pettersson, Andreas
    PROSTATE, 2017, 77 (06) : 647 - 653
  • [30] Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study
    Yao, Song
    Till, Cathee
    Kristal, Alan R.
    Goodman, Phyllis J.
    Hsing, Ann W.
    Tangen, Catherine M.
    Platz, Elizabeth A.
    Stanczyk, Frank Z.
    Reichardt, Juergen K. V.
    Tang, Li
    Neuhouser, Marian L.
    Santella, Regina M.
    Figg, William D.
    Price, Douglas K.
    Parnes, Howard L.
    Lippman, Scott M.
    Thompson, Ian M.
    Ambrosone, Christine B.
    Hoque, Ashraful
    CANCER CAUSES & CONTROL, 2011, 22 (08) : 1121 - 1131